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Background: Dysregulation of the PI3Kinase/AKT pathway is involved in the pathogenesis of many human
malignancies. In acute leukemia, the AKT pathway is frequently activated, however mutations in the PI3K/AKT
pathway are uncommon. In some cases, constitutive AKT activation can be linked to gain-of-function tyrosine
kinase (TK) mutations upstream of the PI3K/AKT pathway. Inhibitors of the PI3K/AKT pathway are attractive
candidates for cancer drug development, but so far clinical efficacy of PI3K inhibitors against various neoplasms has
been moderate. Furthermore, specific MTORC1 inhibitors, acting downstream of AKT, have the disadvantage of
activating AKT via feed-back mechanisms. We now evaluated the antitumor efficacy of NVP-BGT226, a novel dual
pan-PI3K and MTORC1/2 inhibitor, in acute leukemia.
Methods: Native leukemia blasts were stained to analyze for AKT phosphorylation levels on a flow cytometer.
Efficacy of NVP-BGT226 in comparison to a second dual inhibitor, NVP-BEZ235, was determined with regard to
cellular proliferation, autophagy, cell cycle regulation and induction of apoptosis in in vitro and ex vivo cellular
assays as well as on the protein level. An isogenic AKT-autoactivated Ba/F3 model, different human leukemia cell
lines as well as native leukemia patient blasts were studied. Isobologram analyses were set up to calculate for
(super) additive or antagonistic effects of two agents.
Results: We show, that phosphorylation of AKT is frequently augmented in acute leukemia. NVP-BGT226 as well as
NVP-BEZ235 profoundly and globally suppress AKT signaling pathways, which translates into potent antiproliferative
effects. Furthermore, NVP-BGT226 has potent proapoptotic effects in vitro as well as in ex vivo native blasts.
Surprisingly and in contrast, NVP-BEZ235 leads to a profound G1/G0 arrest preventing significant induction of
apoptosis. Combination with TK inhibitors, which are currently been tested in the treatment of acute leukemia
subtypes, overcomes cell cycle arrest and results in (super)additive proapoptotic effects for NVP-BGT226 – but also
for NVP-BEZ235. Importantly, mononuclear donor cells show lower phospho-AKT expression levels and
consequently, relative insensitivity towards dual PI3K-MTORC1/2 inhibition.
Conclusions: Our data suggest a favorable antileukemic profile for NVP-BGT226 compared to NVP-BEZ235 – which
provides a strong rationale for clinical evaluation of the dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute
leukemia.
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Most subtypes of acute leukemia remain difficult to treat.
Patients typically respond to initial induction treatment
regimens - but the majority of adult patients relapse and
die of their disease. Novel therapeutic strategies include
molecular targeted therapeutics, such as tyrosine kinase
inhibitors (TKI) targeting wildtype and gain-of-function
mutated isoforms of the FLT3, KIT and ABL1 tyrosine
kinases [1,2]. However, clinical benefit of these agents is
typically restricted to distinct subsets of patients and/or is
minimal to moderate [3-7].
The phosphoinositide 3-kinase (PI3K)/AKT pathway is a
critical regulator of cellular viability, including insulin me-
tabolism, protein synthesis, proliferation, and apoptosis [8].
Dysregulation of the PI3K kinase/AKT pathway is involved
in pathogenesis of many human malignancies - including
leukemia [9-12]. In many types of solid tumors, activated
AKT signaling can be linked to distinct gene mutations
promoting constitutive AKT activation (e.g. PIK3CA [13]
or AKT [14] mutations) or preventing attenuation of the
AKT signal transduction pathway (PTEN [15,16] muta-
tions). While, these mutations are rare in acute leukemias
[17,18] constitutive phosphorylation of AKT is nevertheless
frequently found. In some cases, activation of AKT can be
linked to gain-of-function tyrosine kinase mutations [19].
However, in most cases of acute leukemia with detectable
activation of the PI3K/AKT pathway, the molecular mech-
anisms are unknown.
Targeting the PI3K/AKT pathway is an attractive thera-
peutic strategy and various small molecule inhibitors are
under clinical investigation [20]. Proof of principle for the
clinical potential to inhibit the PI3K/AKT pathway in
human neoplasms was provided by the successful develop-
ment of rapamycin-derivatives in the treatment of advanced
renal cell carcinoma (RCC), where temsirolimus provides a
significant overall survival benefit [21]. Rapamycin and its
analogues are highly specific inhibitors of the serine/threo-
nine mammalian target of rapamycin kinase (mTOR).
Although an antileukemic activity of rapamycin has been
reported in some patients with AML [22] it is now believed
that several resistance mechanisms may prevent activity of
rapamycin therapy in leukemia: Two mTOR complexes
have been described, of which only the raptor (regulatory
associated protein of mTOR) associated MTOR-complex 1
(a downstream regulator of AKT signaling) is a target of
rapamycin - whereas the rictor (rapamycin-insensitive com-
panion of mTOR)-regulated MTOR complex 2 (a crucial
activator of AKTvia serine-phosphorylation at codon 473) is
not affected by rapamycin inhibition. Even more, MTORC1
inhibition results in increased PI3K/AKT but also MAPK
activity via strong negative feedback loop mechanisms
[23-26]. Consequently, specific inhibitors globally and sus-
tainably suppressing PI3K/AKT signaling pathways may
provide an improved antitumor response.We herein provide evidence that AKT is frequently
phosphorylated and exclusively augmented in native
leukemia samples compared to physiologic mononuclear
cells, making the PI3K/AKT pathway an attractive target
in the treatment of acute leukemia.
In an attempt to globally block PI3K/AKT/MTORC sig-
naling we tested the antileukemic potency of a novel pan
class I PI3K and MTORC1 plus MTORC2 inhibitor, NVP-
BGT226 [27], in comparison to a second dual inhibitor
(NVP-BEZ235 [28]) currently widely under clinical inves-
tigation – including acute leukemia (European Clinical
Trials Database number EUDRACT2011-005050-61).
Our data will provide a strong rationale for clinical
evaluation of NVP-BGT226 in acute leukemias with acti-
vated PI3K/AKT signaling.
Results
AKT is maximally activated in acute leukemia
The PI3K-AKT signal transduction pathway is frequently
activated in acute leukemias (recently reviewed by Polak
and Buitenhuis [29]). Moreover, mice transplanted with
AKT-activated hematopoietic stem cells develop acute
leukemia, indicating the leukemogenic potential of an
activated PI3K/AKT pathway [9].
Maximal activation of AKT results from the phosphor-
ylation of threonine and serine residues at positions 308
(Thr) and 473 (Ser). We addressed whether AKT is acti-
vated in acute leukemia and evaluated phospho-AKT ex-
pression levels of native acute leukemia blood and/or
bone marrow samples (total n=62) collected from adult
patients with newly diagnosed AML or mixed phenotype
and lymphoblastic leukemia.
A flow cytometry-based intracellular immunostain was
set up to assay for Thr308 and Ser473 phosphorylation
patterns in native leukemia blasts. In addition, phospho-
AKT expression levels of physiologic hematopoietic blasts
derived from healthy blood and bone marrow donors
(n=12) were determined. Relative ratios compared to un-
specific IgG-staining were calculated and normalized to
the median expression level of the healthy donor cohort
as shown in Figure 1.
In contrast to the healthy donor cohort, where phospho-
AKT expression levels clustered around 1 (1.0 for Ser472
and 0.97 for Thr308) on a normalized relative expression
level scale (standard deviation 0.3 each), acute leukemia
specimens were frequently found to have augmented phos-
phorylation patterns of AKT. Phosphorylation levels for
both Ser473 as well as Thr308 thereby revealed wide ex-
pression variance ranging from sheer absence to ~17-fold
increase of phosphorylation levels in leukemia samples
compared to the donor cohort. Mean expression levels in
the leukemia cohort were statistically significantly
higher, with an approximately 2-fold elevation of both
Ser473- (p = 0.007) as well as Thr308-phosphorylation
Figure 1 Assessment of Thr308/Ser473 phosphorylation of AKT in native leukemia cells. Intracellular expression levels of 12 blood and
bone marrow donor samples and 62 leukemia patient samples were assessed flow cytometrically. Relative expression analyses compared to an
unspecific IgG control reveal frequent global AKT phosphorylation in hematopoietic benign and malignant mononuclear cells - whereas mean
phosphorylation levels of both Ser473 and Thr308 are statistically significantly increased in leukemia. Augmented phospho-AKT expression is
exclusive to leukemia specimens. Patient characteristics are provided with Additional file 1: Table S1.
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student’s t-test.
Notably, strongly phosphorylated specimens were ex-
clusively found in the acute leukemia cohort (≥ two-fold
expression above normal was found in ~30% of all tested
samples compared to 0% in the donor cohort).
Subanalysis of leukemia blasts derived from bone mar-
row aspirates (n=23) versus peripheral blood specimens
(n=39 (Ser473) or n=38 (Thr308)) revealed no significant
difference of phospho-AKT expression at codon Thr308
(p = 0.06) as well as Ser473 (p = 0.09).
Comparative analysis of expression levels with
leukemia subclassifications, chromosomal or gene muta-
tion status, leukocyte count, age or gender did not
reveal a strong correlation between AKT phosphoryl-
ation levels and clincial parameters. This is in con-
trast to previous reports demonstrating a positive
association of Thr308 phosphorylation with high-risk
cytogenetics and poor prognosis [30] (patient charac-
teristics are provided with Additional file 1: Table S1
with the online version of the article).
NVP-BGT226 has antitumor activity in a PTEN-deficient
acute leukemia cell line model
Our findings of frequent and augmented phosphorylation
of AKT in acute leukemia samples suggest that the AKT
pathway is (auto) activated and may provide a promising
target for directed therapeutics:
Using Jurkat cells, a PTEN-deficient acute lympho-
blastic leukemia cell line rendering AKT signaling path-
ways autoactivated [31], we now provide evidence thatNVP-BGT226 is capable of inhibiting oncogene-driven
PI3K/AKT/MTOR signal transduction pathways in acute
leukemia.
To better compare efficacy in the context of established
compounds, we co-investigated the dual PI3K/MTOR in-
hibitor NVP-BEZ235. This compound has recently been
tested to have significant activity against native leukemia
cells [32].
Cell lysates extracted from Jurkat cells treated with
NVP-BGT226 or NVP-BEZ235 were immunoblotted to-
gether with various phospho-AKT control lysates (treated
with the pan-PI3K inhibitor LY294002 or the specific
MTORC1 inhibitor rapamycin).
The western blot experiment provided with Figure 2A
reveals, that dual inhibition of PI3Kinases and MTOR1/2
complexes by NVP-BGT226 consecutively inhibits serine
(S473) as well as threonine (T308) phosphorylation of
AKT. Moreover, inhibition of AKT activity leads to potent
dephosphorylation of known downstream targets such as
p70S6K and retinoblastoma protein (RB) (required for cell
growth and G1 cell cycle progression) (reviewed in
Panwalkar et al. [33]), ULK1 (a key initiator of MTOR-me-
diated autophagy when dephosphorylated) [34] and
increased cleavage of caspase 3 (a global marker for acti-
vated apoptosis cascades).
While similar potency to inhibit S473-AKT and p70S6
Kinases was observed for NVP-BGT226 as well as
NVP-BEZ235 – the capacity to mediate T308-AKT and
RB dephosphorylation as well as cleavage of caspase 3
was more pronounced for NVP-BGT226 compared to
NVP-BEZ235.
Figure 2 Dual PI3K/MTOR inhibition is effective in PTEN-deficient AKT-activated acute leukemia cells. (A) Exposure of Jurkat cells to NVP-
BGT226, NVP-BEZ235 or Rapamycin reveals preferential consecutive dephosphorylation of AKT at T308 as well as S473 for NVP-BGT226. This results
in suppression of downstream targets including p-T389 p70S6K, p-S575 ULK1, p-S807/811 RB and cleavage of caspase 3. (B) Dose dilution
experiments reveal that NVP-BGT226 as well as NVP-BEZ235 inhibit cellular proliferation in an XTT-based assay. Estimated IC50s, calculated by
linear regression dose-effect plots, are provided at the bottom of each graph. (C) Assessment of induction of apoptosis shows a preferential
proapoptotic effect of NVP-BGT226 when compared to NVP-BEZ235 in an annexin V-based flow cytometry assay. IC50s are provided at the
bottom of each graph.
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duction did translate into a potent antiproliferative ef-
fect for both dual PI3K/MTOR inhibitors (Figure 2B) –
with similar potency in the lower nanomolar range
(IC50s were calculated by linear regression analysis
using dose-effect plots).
Surprisingly, a strong discrepancy was noticed for the
proapoptotic potential of these two inhibitors. Potent in-
duction of apoptosis was observed for NVP-BGT226,
while in contrast, virtually any meaningful proapoptotic
effect was measured for NVP-BEZ235 in an annexin V-
based assay (Figure 2C). This observation is consistent
with immunoblot findings of reduced cleavage intensity
of caspase 3 in NVP-BEZ235 treated cells.NVP-BGT226 inhibits cellular proliferation and overcomes
cell cycle arrest to induce apoptosis in acute leukemia cell
lines
To expand our studies to other oncogene-driven AKT-acti-
vated leukemia cell models, we chose leukemia cell lineswith known gain-of-function tyrosine kinase mutations,
which are prevalent in 30-40% of patients with AML (FLT3
and KIT) or ALL (BCR-ABL1 and FLT3) [2]: The acute
monocytic leukemia cell line MOLM14 (harboring a FLT3
ITD mutation) and the CML blast crisis cell line K562
(harboring a BCR-ABL1 fusion transcript mutation) were
exposed to NVP-BGT226 in a dose dependent manner
and inhibition of cellular proliferation was determined. In
addition, efficacy of NVP-BGT226 was directly compared
to NVP-BEZ235. Both inhibitors proved to be highly sensi-
tive with estimated IC50s in the lower nanomolar ranges
(<100 nM) for both cell lines (Figure 3A).
When looking at the capacity to induce apoptosis in
these leukemia cells, NVP-BGT226 proved to be a
strong inducer of programmed cell death in both cell
lines. However, estimated IC50s were considerably higher
compared to the antiproliferative capacity (Figure 3B).
Interestingly, when treating cells with NVP-BEZ235
only a minor proportion of cells underwent apoptosis
with IC50s that were not reached up to doses of
10 000 nM.
Figure 3 (See legend on next page.)
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Figure 3 Evaluation of dual PI3K/MTOR inhibition in mutant-TK AKT-activated acute leukemia cell lines. (A) MOLM14 cells harboring a
FLT3 ITD and K562 cells harboring a BCR-ABL1 gain-of-function mutation are treated with NVP-BGT226 or NVP-BEZ235 and cellular proliferation is
measured using an XTT-based assay. Both inhibitors reveal high antiproliferative potency in both cell lines. IC50s are provided at the bottom of
each graph. (B) Dual PI3K/MTOR inhibition using NVP-BGT226 or NVP-BEZ235 reveals agent-specific induction of apoptosis in MOLM14 and K562
cells – with NVP-BGT226 the by far more potent agent. Linear regression analysis to calculate IC50s is provided at the bottom of each graph.
(C) Cell cycle analyses of MOLM14 cells treated with either agent demonstrate strong G1/G0 arrest with failure to induce meaningful apoptosis
for NVP-BEZ235 exposed cells. In contrast, NVP-BGT226 treated cells (bottom panels) show a time-dependent increase of the sub-G1/G0 fraction,
indicating apoptotic/dead cells. (D) Similar effects on cell cycle regulation are shown for the K562 cell line treated with either NVP-BEZ235 or
NVP-BGT226 – with a strong G1/G0 arrest for NVP-BEZ235 but potent and time-dependent increase of the apoptotic/dead cell fraction
for NVP-BGT226.
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BEZ235 to induce apoptosis – while both agents are highly
sensitive with regard to inhibition of cellular proliferation,
lead us to hypothesize that divergent cell cycle effects may
be the reason for this observation.
We treated MOLM14 and K562 cells with ~IC50 doses
of NVP-BGT225 (500 nM) or the 2-fold dose of NVP-
BEZ235 (1000 nM) and set up time-dependent cell cycle
analysis by PI-stain flow cytometry. Accumulation of cells
in the G1/G0, S or G2/M phases was monitored 6, 24 and
72 hours after application of either agent.
Of interest, NVP-BGT226 produced a shift of cells from
G2/M and S-phase to the G1/G0 phase – but also mark-
edly increased the proportion of a sub-G0/G1 fraction,
indicating dead/apoptotic cells, with a proportion of
50% (MOLM14, Figure 3C) and 41% (K562, Figure 3D)
72 hours after treatment. In contrast, NVP-BEZ235 lead
to profound und sustained accumulation of cells in the
G0/G1 phase – with only 19% (MOLM14) and respec-
tively 13% (K562) of cells rendering into the sub-G0/G1
fraction after 72 hours of incubation.
Even more, when using high doses (i.e. 10 000 nM), which
kill virtually all cells exposed to NVP-BGT226, strong accu-
mulation of MOLM14 as well as K562 cells within the G1/
G0 fraction was observed for NVP-BEZ235-treated cells
(sub-G1/G0 fractions of only 35% (MOLM14) and 17%
(K562)). This observation argues for a potent and sustained
cell cycle arrest caused by NVP-BEZ235 in these cell lines.
For validation purposes, we set up immunoblotting ex-
periments using whole cell lysates extracted from
MOLM14 or K562 cells treated with either NVP-
BGT226 or NVP-BEZ235 (Figure 4). For comparative
analysis, additional lysates from cells treated with an
ABL1 or FLT3 tyrosine kinase inhibitor (imatinib for
K562 BCR-ABL1 cells, sunitinib for MOLM14 FLT3 ITD
cells) as well as rapamycin were used.
NVP-BGT226 as well as NVP-BEZ235 potently sup-
pressed phosphorylation of AKT at Ser473 as well as
Thr308. As expected, these compounds did not affect phos-
phorylation of FLT3 or ABL1 tyrosine kinases, nor did they
affect phosphorylation patterns of MAPkinases (ERK1/2)
or STAT5, which are known downstream signaling targetsactivated by oncogeneic TK mutations such as FLT3 ITD
or BCR-ABL1.
It has to be noted, that basal phosphorylation levels of
T308-AKT in MOLM14 and K562 cells were relatively
weak to absent – which will be discussed later in more
detail using an isogenic Ba/F3 mutant-TK model.
We furthermore probed for downstream signaling tar-
gets of AKT: Activation of autophagy cascades (via ULK1)
and decreased cell cycle progression in G1 (via dephos-
phorylation of p70S6K and RB) was similarly seen for both
agents – and correlated best with dephosphorylation of
AKT at Ser473. In contrast, only NVP-BGT226 treated
cells managed to override halt of cell growth and induc-
tion of autophagy to induce apoptosis in a cell cycle in-
dependent manner as indicated by increased cleavage
activity at caspase 3 in both tested cell lines.
The western blot experiments hereby support the fin-
dings taken from the cell-based assays for cellular prolif-
eration and induction of apoptosis for both agents.
On a side note, comparative analysis of a specific
MTORC1 inhibitor (rapamycin) revealed consecutive
dephosphorylation of p70S6K – but no concomitant
meaningful inhibition of ULK1 or RB phosphorylation,
no cleavage of caspase 3 and no effect on FLT3 or ABL1
signaling in the tested dose. Importantly, rapamycin did
not suppress AKT phosphorylation – but activates AKT
via a negative feed back loop mechanisms as previously
reported [24,26]. This may counteract clinical efficacy of
single MTORC1 inhibition.
For TKI-treated cells we confirmed potent inhibition of
the corresponding tyrosine kinase, as well as downstream
signaling pathways including MAPKinases, STATs as well
as AKT [35,36]. However, dephosphorylation of the AKT
pathway was less pronounced compared to STAT5 or
ERK1/2 inhibition, leaving downstream signals (partially)
phosphorylated. This observation argues for a potential
rescue mechanism of TKI monotherapy, which may be
overridden by combination approaches: As indicated in
our immunoblot panel, a combination of TKI with PI3K/
AKT signaling inhibitors, such as rapamycin or dual
PI3K/MTOR inhibitors, potently and globally sup-
presses AKT signaling pathways as well as mutant-TK
Figure 4 Mutant-TK mediated AKT signaling pathways are potently and globally suppressed by dual PI3K/MTOR inhibition.
Immunoblotting of equally loaded whole cell extracts reveals strong consecutive suppression of AKT signaling pathways in the acute leukemia
cell lines MOLM14 or K562, which harbor known autoactivating tyrosine kinase (TK) mutations (MOLM14: FLT3 ITD; K562: BCR/ABL1). TKI and
specific MTORC1 inhibition by rapamycin reveal a differential inhibition profiles. Jurkat cells are used as positive controls for activated AKT
signaling; PI3K-inhibited Jurkat cells (treated with LY294002) serve as negative controls. Actin blotting is used as a loading control.
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signaling.
To provide a mathematical tool to describe the combi-
nation effect of two agents, we performed fixed ratio dilu-
tion experiments to create isobolograms using a method
of Chou and Talalay [37]. Cells were treated with the
single agents and fixed ratios of NVP-BGT226 or NVP-
BEZ235 plus sunitinib (MOLM14 cells) or imatinib (K562
cells) to assess for induction of apoptosis. This was used
to create isobolograms (Figure 5). Combination of NVP-
BGT226 with sunitinib in MOLM14 cells (Figure 5A)
resulted in an experiment point that falls to the left of
the predicted line of additive effect when taking ED90
(i.e. 90% apoptotic cells) as the experimental end point
(indicating a superadditive effect). Similar results were
achieved for NVP-BGT226 combined with imatinib in
K562 cells with an experiment point lying on (ED50) or
falling to the left (ED90) of the predicted line of additive
effect (Figure 5B).
Calculation of combination indices (CI) revealed a CI
close to 1 (i.e. additive effect) for ED50s in both cell lines
and a CI < 1 for ED90 – indicating synergy (i.e. super-
additive effects).
Due to the moderate proapoptotic effect of NVP-
BEZ235 when administered as single agent, calculation ofisobolograms and resultant CIs were restricted to ED25-
50 concentrations for NVP-BEZ235+TKI combinations.
Nevertheless, a strong synergistic effect was revealed for
both combinations of NVP-BEZ235 plus sunitinib in FLT3
ITD positive MOLM14 cells (Figure 5C), or NVP-BE235
plus imatinib in BCR-ABL1 positive K562 cells (Figure 5D)
with CIs well smaller than 1. Additionally, estimated
ED90s are provided along with each figure as well.
These findings indicate that a combination approach may
override the G1/G0 arrest observed for NVP-BEZ235
monotherapy – which is supported by increased cleavage
of caspase 3 in the western immunoblot experiments
when combined with TKI (Figure 4).Leukemia-driving tyrosine kinase mutations trigger
consecutive AKT serine phosphorylation of codon 473
and threonine phosphorylation of codon 308
In order to minimize cell type specific off-target effects
to validate our findings for the mutant FLT3 ITD cell
line MOLM14 and the BCR-ABL1 positive cell line
K562, we established an isogenic Ba/F3 cell line
model transfected with AKT-autoactivating FLT3 ITD or
BCR-ABL1 mutations. We further comparatively ex-
tended our studies to additional leukemia-associated
Figure 5 Isobologram analyses of combined dual PI3K/MTOR plus TKI treatment in mutant-TK activated leukemia cells. Co-treatment of
specific TKI (sunitinib to target FLT3 ITD in MOLM14 cells (A and C), imatinib to target BCR-ABL1 in K562 cells (B and D) with either NVP-BGT226
(A and B) or NVP-BEZ235 (C and D) reveal additive to synergistic proapoptotic effects for the combination treatment: Isobolograms are
provided, showing experimental points that fall on or below the predicted line of additive effect, indicating additive to superadditive effects for
all tested endpoints. Calculations of combination indices (CI) provide a mathematical number to describe the degree of synergy for the
respective endpoint.
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transfectants are provided with Table 1).
Immunoblotting for phospho-AKT was performed after
successful transfection and weaning of IL3-dependent
growth (true autoactivating TK mutations result in IL3-in-
dependent growth) and found that AKT activation
increases after transfection of plasmid vectors encoding
for a FLT3 ITD, FLT3 D835V, KIT D816Y or BCR-ABL1
isoform.
While cytokine-starved parental BaF3 cells did only re-
veal moderate, if any, phosphorylation levels of AKT,
IL3-stimulated or oncogene-transfected Ba/F3 cells did
globally activate AKT on codons Thr308 as well as
Ser473. Notably, TK-mediated activation of AKT was by
far more pronounced compared to physiologic, cytokine
(IL3)-mediated activation of AKT (Figure 6A).
We tested our model by treating Ba/F3 cells
transfected with the gain-of-function FLT3 D835V muta-
tion with either NVP-BGT226 or NVP-BEZ235 and
probed for T308- or S473-phosphorylated AKT isoforms
in a western immunoblot using whole cell lysates. Both
inhibitors potently and globally suppressed AKT
phosphorylation of initially maximally activated AKT
(Figure 6B). Jurkat cells treated with well established
PI3K inhibitors (Wortmannin, LY294002) served as
controls.NVP-BGT226 displays antiproliferative and proapoptotic
activity in mutant-tyrosine kinase mediated AKT-activated
Ba/F3 isogenic cells
We next utilized our Ba/F3 model to evaluate the mutant-
TK specific antiproliferative effect of either NVP-BGT226
or NVP-BEZ235 in an isogenic cellular background. Both
agents revealed compound-specific – but also distinct mu-
tation-specific activity, with the parental cell line (stimu-
lated with IL3) being the least sensitive for both tested
agents (estimated IC50s by regression dose effect ana-
lysis ~2400 nM for NVP-BEZ235 and ~800 nM for
NVP-BGT226). BCR-ABL1, FLT3 D835V and KIT D816Y
transfectants displayed an intermediate sensitivity pattern (esti-
mated IC50s for NVP-BEZ235 ~10-130 nM and ~65-180 nM
for NVP-BGT226) whereas FLT3 ITD demonstrated high
sensitivity for both agents with IC50s below 10 nM. Repre-
sentative dose vs. effect graphs are shown in Figure 7A/B.
A summary of achieved IC50s is provided in Table 1 - to-
gether with additional (mutant-) TK isoforms tested.
When testing for induction of apoptosis, NVP-BGT226
proved to be highly potent in virtually all tested cell lines,
with transfectant-specific IC50s raging from ~120-1800
nM (again, the parental IL3-stimulated cell line being the
least sensitive). In contrast, the high capacity to inhibit
cellular proliferation for NVP-BEZ235 did not similarly
translate into potency to induce apoptosis for all tested
Figure 6 Western immunoblot analyses of mutant-TK Ba/F3 cells as a cell model for activated AKT-signaling. (A) Transfection of
leukemia-driving mutant-KIT, FLT3 or BCR-ABL1 isoforms into a hematopoietic IL3-dependent Ba/F3 cell line leads to global increase of AKT
phosphorylation as assayed by immunoblotting of whole cell extracts. Phosphorylation of Ser473 and Thr308 increases in response to IL3
stimulation - and further augments in cells transfected with a gain-of-function mutant-TK. Tubulin blotting is used as loading control. (B) An
immunoblot experiment with Ba/F3 cells transfected with a FLT3 D836V mutation treated with NVP-BGT226 or NVP-BEZ235 and probed for
phosphorylation patterns of AKT is shown. Jurkat cells are used as positive controls. Jurkat cells treated with PI3K inhibitors (Wortmannin,
LY294002) serve as negative controls for AKT phosphorylation. Actin blotting serves as a loading control.
Table 1 Isogenic Ba/F3 model: apoptosis and proliferation assays - IC50s
NVP-BEZ235 IC50 (nM) NVP-BGT226 IC50 (nM)








Parental (w/ IL3) Not reached* 3 6 Parental (w/ IL3) 1821 7 99
KIT WT 1396 32 85 KIT WT 463 48 97
KIT D816V Not reached 4 23 KIT D816V 1791 7 99
KIT D816F 1244 40 87 KIT D816F 258 87 89
KIT D816Y 1363 5 73 KIT D816Y 118 89 96
FLT3 WT 8296 38 40 FLT3 WT 345 41 99
FLT3 S451F 741 49 70 FLT3 S451F 125 93 99
FLT3 ITD Not reached 19 27 FLT3 ITD 1079 38 98
FLT3 K663Q Not reached 17 16 FLT3 K663Q 1111 26 98
FLT3 D835V 458 52 86 FLT3 D835V 163 84 98
FLT3 D835Y Not reached 19 28 FLT3 D835Y 1073 33 98
FLT3 N841H Not reached 19 22 FLT3 N841H 1206 18 99
BCR/ABL1 Not reached 38 39 BCR/ABL1 262 56 97








Parental (w/ IL3) 2398 89 98 Parental (w/IL3) 828 100 86
KIT WT 6 12 11 KIT WT 6 24 13
KIT D816V 8 40 38 KIT D816V 153 110 47
KIT D816Y 72 64 62 KIT D816Y 65 112 26
FLT3 WT 7 33 28 FLT3 WT 40 66 27
FLT3 K663Q 91 57 51 FLT3 K663Q 277 79 52
FLT3 ITD 7 13 4 FLT3 ITD 3 4 9
FLT3 D835V 10 50 51 FLT3 D835V 141 58 47
FLT3 D835Y 5 37 30 FLT3 D835Y 35 65 33
FLT3 N841H 9 43 47 FLT3 N841H 89 110 38
BCR/ABL1 131 58 50 BCR/ABL1 183 73 52
*IC50s not reached (> 5 000 nM).
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Figure 7 Mutant-tyrosine kinases sensitize Ba/F3 cells to dual PI3K/MTOR inhibition. Ba/F3 cells transfected with KIT D816Y, FLT3 ITD, D835V
or BCR-ABL1 isoforms were exposed to NVP-BEZ235 (A) or NVP-BGT226 (B) in a dose-dependent manner. Dual PI3K/MTOR inhibition results in
transfectant- and inhibitor-specific inhibition of cellular proliferation (XTT assay) with a higher sensitivity of cells transfected with leukemia-driving
mutant-TK (KIT, FLT3, ABL1) isoforms compared to the (IL3-stimulated) parental cell line. When setting induction of apoptosis as the experimental
endpoint, NVP-BEZ235 (C) was less effective compared to NVP-BGT226 (D), in all tested transfectants. IC50s, estimated by linear dose regression
analysis, are provided along with several more transfectants in Table 1. (E) On the protein level, IL3-stimluated or mutant-TK Ba/F3 transfected
cells show similar potent AKT dephosphorylation of Ser473 but cell strain specific cleavage of caspase 3 upon NVP-BGT226 or NVP-BEZ235
exposure. Parental, cytokine-depleted Ba/F3 cells do not express phosphorylated AKT and neither NVP-BGT226 nor NVP-BEZ235 induces cleavage
of caspase 3.
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which were highly inhibited with regard to cellular pro-
liferation, did only show moderate induction of apoptosis
towards NVP-BEZ235 (IC50 not reached up to tested
doses of 10 000 nM, proportion of apoptotic cells at 5000
nM: 27%). In analogy, BCR-ABL1 transfected cells failed
to achieve IC50 as well, with a proportion of 39% apop-
totic cells at 5000 nM). These findings are in line with our
results for the corresponding tested human leukemia cell
lines. Notably, other transfectants (e.g. FLT3 D835V and
KIT D816Y) retained some level of sensitivity with regard
to induction of apoptosis. Representative dose vs. effectgraphs are shown in Figure 7C/D. A full list of IC50s for
both agents and additionally tested mutant-TK Ba/F3 cells
are provided with Table 1.
We confirmed our observations at the protein level
and treated Ba/F3 parental (+/− IL3), FLT3 ITD, FLT3
D835V, KIT D816Y or BCR-ABL1 transfected cells with
NVP-BGT226 or NVP-BEZ235 to probe whole cell ly-
sates for AKT phosphorylation in an immunoblot. Dual
inhibition of PI3Kinases and MTOR1/2 lead to potent
AKT dephosphorylation of initially activated AKT in
IL3-stimulated or mutant-TK activated cells in the low
nanomolar range (Figure 7E). This went along with the
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cellular level. In line with our cellular apoptosis assays,
immunoblotting for cleaved caspase 3 as an indicator for
induced apoptosis again revealed that higher doses are
needed to induce programmed cell death in these cell
lines (if any, when looking at NVP-BEZ235). These find-
ings argue for a complex regulation of programmed cell
death, which will need to be studied in more detail in
future studies. One hypothesis may state that induction
of apoptosis is mediated via Thr308: We observed a par-
ticular high phosphorylation pattern of Thr308 in cells
transfected with the tyrosine kinase domain (TKD)-mu-
tated FLT3 D835V and KIT D816Y isoforms in our as-
says (see Figure 6). Interestingly these were the cell lines
to display the highest rates of apoptosis after treatment. In
contrast BCR-ABL1 or FLT3 ITD transfectants, presenting
with comparably lower p-T308 AKT levels, were by far
less sensitive towards NVP-BEZ235 with regard to induc-
tion of apoptosis (compare Figure 7C). These observations
are in line with Thr308 phosphorylation levels seen in
MOLM14 and K562 cell lines, which were relatively weak
to absent (see also Figure 4).
NVP-BGT226 displays antileukemic activity in native
leukemia blasts treated ex vivo
To evaluate, whether our in vitro data derived from
leukemia cell lines and mutant-TK cell line models trans-
late into a clinically meaningful antiproliferative effect in
native leukemia cells, we treated an acute leukemia sample
taken from a patient suffering from FLT3 mutant-TKD2
positive AML and a sample from a patient with AML
tested negative for FLT3 or KIT mutations with varying
concentrations of NVP-BGT226 or NVP-BEZ235 and
tested for the capacity to inhibit cellular proliferation
ex vivo using an XTT-based assay. The FLT3 TKD2 posi-
tive leukemia sample (pat. 556) revealed high sensitivity
towards NVP-BGT226 as well as NVP-BEZ235 with cal-
culated IC50s in the low nanomolar range in a dose-effect
plot. In contrast the AML sample lacking mutant-TK
isoforms (pat. 303) was virtual insensitive towards both
agents with IC50s well above 5000 nM. Importantly,
mononuclear cells extracted from an aspirate of a bone
marrow donor (bm-donor 552) revealed a sensitivity pro-
file of IC50s > 1000 nM for both compounds. Dose-effect
plots were created for tested patient samples to calculate
IC50s, which are provided in Table 2 along with AKT ex-
pression patterns (exemplary dose-effect plots to calculate
IC50s is provided in Additional file 2: Figure S1A; patient
characteristics are provided in Additional file 1: Table S1).
The findings of equipotent sensitivity profiles of NVP-
BGT226 and NVP-BEZ235 with regard to inhibition of
cellular proliferation in native AKT-activated leukemia
cells are in line with our in vitro data provided above.
Notably, the PI3K/AKT/MTOR pathway is a target ofNVP-BGT226 as well as NVP-BEZ235 in native acute
leukemia cells as verified in an immunoblot experiment
for two patient samples with newly diagnosed acute
leukemia (Additional file 2: Figure S1B, provided with
the online version of the article). This further underlines
and validates the herein described in vitro and ex vivo
data rather than arguing for off-target effects.
Correlation of ex vivo responses to NVP-BGT226 and
NVP-BEZ235 with AKT expression levels suggests that
augmented activation of AKT (compared to healthy
bone marrow donors), i.e. phosphorylation of Thr308 as
well as Ser473 but not mere AKT protein levels, may be
a requisite for inhibition of cellular proliferation in re-
sponse towards dual PI3K/MTOR inhibition. Clearly,
analysis of pan-AKT protein levels may not predict for
response, as AKT expression was highest in the AML
sample refractory towards both inhibitors (Table 2).
Next, we studied, whether NVP-BGT226 and NVP-
BEZ235 are capable of inducing apoptosis in native
leukemia samples. Leukemia blasts extracted from acute
myeloid, promyelocytic or lymphoid leukemia with or
without detectable TK mutations were treated with
NVP-BGT226 or NVP-BEZ235 in dose dilution series
and apoptosis was assessed by an Annexin V/PI stain.
In analogy to our in vitro data described before, both
agents demonstrated variable apoptosis induction. Not-
ably, NVP-BGT226 proved to be the more potent drug
with high effectivity and IC50s in the lower nanomolar
range in some patient samples (Table 2). Of note, native
mononuclear cells derived from bone marrow donors re-
vealed much higher IC50s for both agents. Analysis of
AKT expression levels suggest that global activation of
AKT with augmented phosphorylation of Ser473 as well
as Thr308 beyond a baseline set as 1 on a normalised
AKT expression scale is a prerequisite to predict response
towards the dual PI3K/MTOR inhibition. However, this
observation will need prospective verification on a larger
patient cohort.
Discussion
PI3K/AKT signaling controls key signaling pathways in-
volved in the maintenance of cellular viability and proli-
feration in many cells and tissues. Not surprisingly,
activation of AKT is increased in many human malignan-
cies and gain-of-function mutations are frequently found
within PI3K/AKT axis, especially in solid tumors, making
the PI3K/AKT signaling pathway an attractive target for
molecular therapeutics.
In acute leukemia, activating mutations in the PI3K/AKT
signaling cascade are rare – but nevertheless, we and
others have reported frequent activation of AKT (i.e. phos-
phorylation of Thr308 and Ser473): In this study, we dem-
onstrate global phosphorylation of AKT in native acute
leukemia samples. Average expression levels are thereby
Table 2 Leukemia models: Comparison of response rates and AKT expression levels
















Normalised to mean expression of all donors GeoMean
(pT308+pS473+panAK)
IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM)
538 (donor) 0,8 0,7 0,8 0,77 Not reached 1779
554 (donor) 0,9 1,0 0,7 0,87 Not reached 3814
290 1,7 1,5 2,4 1,82 71 4
368 1,9 2,7 1,5 1,96 3182 149
527 0,8 1,9 1,3 1,25 6824 12
528 2,4 2,5 1,5 2,07 371 12
532 2,8 1,2 1,2 1,59 653 25
552 (donor) 1,3 1,3 1,5 1,34 1019 1081
303 0,9 1,6 2,0 1,38 6142 5590
556 1,5 1,9 1,2 1,48 24 32
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hematopoietic mononuclear cells derived from healthy do-
nors. Moreover, augmented expression levels are exclu-
sively found in the leukemia cohort.
The mechanisms of AKT activation in acute leukemia
are only partially understood. One mechanism of consti-
tutive phosphorylation of AKT can be explained by the
presence of gain-of-function mutant tyrosine kinases,
which are found in approximately 30-40% of adult AML
and ALL. However, we did not find an exclusive correl-
ation of phospho-AKT expression levels and the pres-
ence of TK mutations, suggesting other mechanisms,
which render AKT autoactivated in leukemia cells.
Evaluation of the triggering mechanisms are topic of on-
going research.
Globally targeting the AKT signaling pathways may be a
promising approach to treat acute leukemia. We herein
evaluated the antileukemic efficacy of the novel dual PI3K/
MTOR inhibitor NVP-BGT226, a pan-PI3Kinase inhibitor
also targeting the rapamycin-sensitive MTOR complex 1
as well as the rapamycin-insensitive MTOR complex 2.
Using defined cell line models, and primary leukemia
patient as well as donor samples we studied the distinct
effects of NVP-BGT226 on cellular proliferation, cell cycle
progression and induction of apoptosis. Thereby we com-
pared NVP-BGT226 to a second dual inhibitor, NVP-
BEZ235, which is currently under investigation in a phase I
study for relapsed/refractory ALL or AML (European Clin-
ical Trials Database number: EUDRACT2011-005050-61).
Our cell models included cell lines with defined geno-
mic alterations rendering the AKT signaling pathway
autoactivated, i.e. (i) a PTEN-deficient acuteT-lymphoblastic
leukemia cell line (Jurkat), (ii) patient-derived leukemia
cell lines with well described TK-mutations (MOLM14harboring a FLT3 ITD mutation and K562 harboring a BCR-
ABL1 fusion transcript mutation), (iii) engineered Ba/F3 cell
lines transfected with mutant tyrosine kinases expressed in
an otherwise isogenic cellular background and (iiii) native
ex vivo acute leukemia cells, with or without a defined
TK-mutation, derived from consented patients with newly
diagnosed acute leukemia. In addition, we comparatively
studied native physiologic mononuclear cells derived from
bone marrow donors.
In PTEN-deficient Jurkat cells, NVP-BGT226 proved
to potently inhibit cellular proliferation in the low
nanomolar range. The sensitivity profile is thereby in the
same range compared to the additionally tested dual
PI3K/MTOR inhibitor, NVP-BEZ235.
It was previously noted, that the predominant antitumor
effect of inhibitors of PI3K/AKT/MTOR signaling cascades
is mediated via inhibition of cellular proliferation rather
than induction of apoptosis [32,38,39]. Surprisingly how-
ever, NVP-BGT226 proved to have genuine proapoptotic
efficacy – whilst the proapoptotic effect achieved by NVP-
BEZ235 was, as expected by previous reports, at most
moderate.
To model the effects of NVP-BGT226 and NVP-BEZ235
on mutant-TK triggered AKT activation, we chose two well
established acute leukemia cell lines harboring a FLT3 ITD
mutation (MOLM14) or a BCR-ABL1 mutation (K562).
Similar to the findings for Jurkat cells, both inhibitors,
proved to be highly potent in inhibiting cellular proli-
feration. However again, NVP-BEZ235 only moderately
induced a meaningful proapoptotic effect, whereas NVP-
BGT226 was a strong inducer of the programmed cell
death machinery.
As the AKT pathway controls cell cycle checkpoints, we
speculated that the discrepancy may be due to
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indeed, a strong and sustained G0/G1 arrest was observed
for NVP-BEZ235 preventing cells to undergo apoptosis.
On the protein level, where both agents were similarly
targeting downstream proteins controlling cell cycle pro-
gression (such as S6Kinases and RB) or ULK1-induced
autophagy, only NVP-BGT226 was capable to override
cell protective mechanisms to potently induce apoptosis.
We speculated that the cell cycle arrest induced by
NVP-BEZ235 might be overcome by combination ap-
proaches: TKI, for which we demonstrated insufficient
global suppression of AKT signaling pathways – but
additional effects on alternative survival pathways such
as MAPK and STAT signaling, may be an attractive mo-
lecularly defined partner to combine with dual PI3K/
MTOR inhibitors. Indeed on the protein level, combin-
ation of TKI with either of the tested dual PI3K/AKT in-
hibitors efficiently and globally shut down AKT signaling
pathways - as well as additional targets (ERK1/2, STAT5)
triggered by mutant-TKs.
In an attempt to mathematically define the extend of
combination efficacy, we established isobologram assays
to compute combination indices (CI). Together, calculated
CIs for TKI plus dual PI3K/MTOR inhibitor treatment
were close to or smaller than 1, indicating an additive to
superadditive (synergistic) effect for all tested endpoints.
Notably, combination of TKI with NVP-BEZ235 was
capable to override cell cycle arrest seen for NVP-
BEZ235 monotherapy to potently induce apoptosis in
leukemia cells.
One might speculate that cell-type specific off-target
effects may have prevented cells to undergo apoptosis.
To confirm our findings, we established an isogenic
Ba/F3 cell line model transfected with FLT3 ITD (corre-
sponding to MOLM14 cells) or BCR-ABL1 (correspond-
ing to K562 cells) mutations. NVP-BGT226 revealed
high potency to inhibit cellular proliferation in the same
range as NVP-BEZ235.
As expected, while meaningful proapoptotic effects
were achieved by NVP-BGT226 in all cell strains, FLT3
ITD and BCR-ABL1 transfected Ba/F3 cells were only
moderately sensitive towards NVP-BEZ235.
We additionally created several more Ba/F3 cell lines
transfected with tyrosine kinases harboring known
leukemia-driving gain-of-function mutations and tested
for NVP-BGT226 and NVP-BEZ235 sensitivities. While
NVP-BGT226 again displayed a beneficial pro-apoptotic
profile for all tested transfectants, NVP-BEZ235 surpri-
singly retained meaningful proapoptotic activitiy in some
cell strains. Two sensitive transfectants (harboring a FLT3
D835V or KIT D816Y mutation) were immunoblotted –
and showed higher elevated threonine 308 phospho-
rylation levels compared to FLT3 ITD or BCR-ABL1
transfected cells.This observation may have far-reaching consequences:
It is tempting to speculate that activation of the PI3K/
AKT pathway is at least in part dependent on the
specific type of TK gain-of-function mutation and that
different gain-of-function mutations may display a very
distinct pattern of activated PI3K/AKT signaling cas-
cades. This again might influence the susceptibility of
cells towards PI3K/AKT-targeted inhibitors. In this
context, it is well described for TKI therapy of CML and
GIST and has recently been shown for TKI therapy in
acute leukemia as well, that resistance towards TK-inhib-
itors is often caused by secondary mutations within the
tyrosine kinase domain (such as point mutations at FLT3
D835) of the respective tyrosine kinase [40]. Such muta-
tions may activate AKT signaling, as previously demon-
strated for imatinib-resistant GIST tumors [41], and
sensitize cells towards targeted therapies.
We tested this theory using two cell models compar-
ing primary TK-sensitive mutations with secondary
TK-insensitive mutations: The first model consists of a
mast cell leukemia cell line (HMC1.1), which harbors an
imatinib-sensitive KIT V560G mutation – and a deriva-
tive sister cell line (HMC1.2), which is characterized by
a secondary activation loop KIT D816V mutation,
rendering the cells insensitive towards imatinib [42,43].
Additionally we tested the GIST solid tumor cell line
GIST882 (harboring an imatinib-sensitive KIT K642E mu-
tation) [44] with a second cell line, which was established
from a patient with relapsing GIST under imatinib therapy
(GIST48) [45]. This cell line harbors a primary homo-
zygous juxtamembrane KIT mutation (V560D) plus a sec-
ondary heterozygous imatinib-insensitive activation loop
mutation (D820A).
Indeed, in our experiments, NVP-BEZ235 as well as
NVP-BGT226 potently induced apoptosis irrespective of
the sensitivity profile towards TKI – with NVP-BGT226
again being the more potent inhibitor (data provided as
Additional file 3: Figure S2 with the online version of
the article). Together, dual PI3K/MTOR inhibitors such
as NVP-BGT226 or NVP-BEZ235 may be of special clin-
ical value in the desperate case of tumor progress due to
TKI-resistance, which is an ever increasing problem in
the treatment of relapsed acute leukemia. The underlying
molecular mechanisms determining the susceptibility of
cells towards induction of apoptosis as well as sensitivity
towards NVP-BGT226 or NVP-BEZ235 (e.g. higher bind-
ing affinities and alternative (unknown) targets) is elusive
and will need to be answered in future studies.
Most importantly however, we did show that dual inhi-
bition of pan class I PI3Kinases plus MTOR1/2 com-
plexes does translate into a genuine antiproliferative but
also proapoptotic effect in native leukemia cells treated
ex vivo – with NVP-BGT226 being the more potent
drug with regard to induction of apoptosis. Augmented
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AKT protein levels seemed to be a prerequisite for treat-
ment response. However, this observation will need
prospective validation. Furthermore, efficacy was not re-
stricted to leukemia samples with identified genomic
mechanisms of AKT activation (such as tyrosine kinase
mutations), suggesting alternative mechanisms of acti-
vation yet to be identified.
Of note, among the native leukemia samples treated
successfully ex vivo with either agent were cases from
patients with poor prognostic features lacking effective
therapeutic options. For example, both agents were
effective in AML with mutant FLT3, including a patient
with TKI-resistant FLT3 ITD (B1 sheet)-positive AML [46]
who had relapsed after allogeneic stem cell transplantation.
Other refractory AML cases with ex vivo sensitivity of
cells to PI3K/MTOR inhibition included a relapsed
elderly patient with MLL-rearranged AML. In this con-
text, it has been shown that MLL rearrangements associ-
ate with high EVI1 expression, which predicts for dismal
prognosis [47]. Further, Yoshimi and colleagues re-
cently have demonstrated that EVI1 activates AKT
signaling due to loss of PTEN activity [48]. As there
are currently no effective therapy options for treat-
ment of EVI1-associated AML, targeting the PI3K/
AKT/MTOR pathway may be particularly of interest.
Preliminary data of an early phase I trial of NVP-
BEZ235 in the treatment of advanced unresectable solid
tumors demonstrated good tolerability with no dose-
limiting toxicities. Notably, hematologic side effects
were seen – but were mild to moderate with reversible
anemia after treatment discontinuation [49]. Currently,
a study evaluating efficacy of NVP-BEZ235 in acute
leukemia is recruiting (European Clinical Trials Data-
base number EUDRACT2011-005050-61).
In our studies, NVP-BGT226 proved to be the more
effective agent with regard to antileukemic efficacy. Ex
vivo treatment revealed IC50s in the nanomolar or lower
micromolar range and thus NVP-BGT226 may be an at-
tractive agent for targeted treatment of acute leukemias.
A very recent phase I study evaluating NVP-BGT226 in
advanced solid tumors demonstrated variable antitumor
activity [50]. In this context, another recent report demon-
strated that NVP-BGT226 results in cell cycle arrest
in pancreatic cancer cell lines [51], which is in clear con-
trast to our findings. This may argue for the rather low
antitumor efficacy reported in the above mentioned phase
I trial in advanced solid tumors. Our data clearly states a
differential biological behavior of acute leukemia cells with
regard to regulation of cell growth, cell cycle progression
and induction of apoptosis, which may still support spe-
cific clinical testing of NVP-BGT226 in acute leukemia.
Moreover, in our studies, normal mononuclear cells
were significantly less inhibited by dual PI3K/MTORinhibition than leukemia cells, indicating a therapeutic
gap of these agents in the treatment of acute leukemia
without significant suppression of normal hematopoiesis.
Nevertheless, as NVP-BGT226 targets physiologic cells
in the highest tested doses, clinical evaluation will need
to address potential side effects on the hematopoietic
progenitor/stem cell pool. However, even in the case of
significant stem cell suppression, NVP-BGT226 may still
serve as an attractive agent for bridging-to-transplant stra-
tegies or allogeneic transplant conditioning regimens –
especially for high-risk or elderly patients lacking other
options.
Conclusion
In summary, dual PI3K/MTOR inhibition is highly ef-
fective against acute leukemia cells, both in vitro as well
as ex vivo. This efficacy extends to leukemia blasts from
patients with high-risk features. Notably, the novel dual
PI3K/MTOR inhibitor NVP-BGT226 reveals extraordin-
ary potency to inhibit proliferation as well as to induce
apoptosis in the nanomolar range against a broad range
of cell lines and ex vivo leukemia samples tested. Fur-
thermore, NVP-BGT226 did not induce G1/G0 cell cycle
arrest seen for other PI3K inhibitors, such as NVP-
BEZ235 in our studies, making NVP-BGT226 a highly
promising agent for clinical testing in acute leukemia.
This may include combination approaches as well as
targeted therapy of TKI-resistant leukemias. Based on our
studies, clinical evaluation of this agent for targeted treat-
ment of acute leukemia subtypes is strongly indicated.
Methods
Cell Culture
Ba/F3 cell lines were obtained through the American Type
Culture Collection (ATCC, Manassas, VA). The MOLM14
cell line was acquired through the Fujisaki Cell Center
(Okayama, Japan). The MLL-AF9 fusion positive acute
monocytic leukemia cell line MOLM-14 harbors a hetero-
zygous FLT3 ITD mutation [52].
The T-lymphoblastic cell line Jurkat and the CML blast
crisis cell line K562 were obtained from the Deutsche
Sammlung für Mikroorganismen und Zellkulturen (DSMZ,
Braunschweig, Germany).
The human mast cell leukemia cell line HMC1.1, har-
boring an imatinib-sensitive KIT V560G mutation [42],
and the sister cell line HMC1.2, harboring an additional
imatinib-insensitive KIT D816V mutation [43] were
provided by Prof. Heinrich, OHSU, Oregon. The GIST
tumor cell lines GIST48 and GIST882 were kindly pro-
vided by Dr. Kopp, (University of Tübingen, Germany).
GIST882 is harboring a KIT K642E mutation [44];
GIST48 was established from a patient with relapsing
GIST under imatinib therapy (GIST48). This cell line
harbors a primary juxtamembrane KIT mutation plus a
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domain [45].
Cells were cultured in RPMI 1640, supplemented with
10% fetal bovine serum (GIBCO/Invitrogen, Darmstadt,
Germany or Biochrom AG, Berlin, Germany), 1% peni-
cillin G (10,000 units/mL), and streptomycin (10,000
μg/mg) and 2 mmol/L L-glutamine. In addition, pa-
rental Ba/F3 cells were supplemented with 10 ng/ml of
mouse-IL3. Negativity for mycoplasma contamination
was confirmed using the pluripotent PCR Mycoplasma
test Kit (AppliChem, Darmstadt, Germany). Cell lines
harboring a mutant KIT, FLT3 or BCR-ABL1 were se-
quence confirmed.
Patient specimens
Bone marrow aspirate and peripheral blood samples from
consented patients with acute leukemia as well as samples
from healthy blood and bone marrow donors were col-
lected in 5000 U heparin with the approval of the ethics
committee of the Medical Faculties of the University of
Tübingen or the University of Ulm. Mononuclear cells
were isolated by Ficoll-Hypaque density gradient fraction-
ation. Cells were cultured in DMEM medium, supple-
mented with 20% fetal bovine serum (GIBCO/Invitrogen,
Darmstadt, Germany or Biochrom AG, Berlin, Germany),
1% penicillin G (10,000 units/mL), and streptomycin
(10,000 μg/mg) and 2 mmol/L L-glutamine.
Antibodies and reagents
The dual pan class I PI3K AND MTOR complex 1 and
2 inhibitors NVP-BEZ235 [28] and NVP-BGT226 [27],
two imidazo[4,5-c]quinoline derivatives competitively
binding to the ATP-binding cleft of these enzymes were
provided by Novartis (Basel, Switzerland). Stock solu-
tions were created according to the manufacturer’s in-
structions. Rapamycin and the PI3K inhibitors LY294002
and Wortmannin were obtained from Cell Signaling
(Danvers, MA). The TKI dasatinib (formerly BMS-354825)
and sunitinib (formerly SU11248) were obtained from
the University of Tübingen Hospital Pharmacy and
dissolved in DMSO to create 10 mmol/L stock solutions
and stored at −20°C.
Rabbit anti-panAKT, panFLT3, panABL1 or anti-
cleaved caspase 3 antibodies were used at a 1:500 to
1:1000 dilution. Rabbit anti-phospho-AKT antibodies
detecting phosphorylated isoforms of T308-AKT, S473-
AKT, S807/811-RB, S575-ULK1, T389-p70S6K, Y694-
STAT5, FLT3, ABL1 or T202/Y204-ERK1/2 were used
at a 1:250 to 1:1000 dilution. An anti-actin mouse
monoclonal antibody was used as a loading control. All
antibodies, if not otherwise indicated, were purchased
from Cell Signaling Technology.
As controls for AKT Thr308- and Ser473-phosphorylation
we used Jurkat cells untreated (phosphorylated positivecontrol) or treated with LY294002 orWortmannin (negative
controls lacking T308/S473 phosphorylation).
Infrared dye-conjugated secondary goat anti-rabbit and
anti-mouse antibodies to use in a LI-COR® imaging detec-
tion system were used according to standard protocols
(LI-COR Biosciences, Lincoln, NE). For flow cytometry
studies, fluorescent dye-conjugated secondary goat anti-
rabbit or anti-mouse antibodies were used according to
standard protocols. Cell Signaling anti-rabbit IgG(H+L),F
(ab’)2Fragment Alexa Fluor conjugate antibodies were
used to assess expression levels provided in Table 2. The
Invitrogen Zenon Alexa Fluor labeling kit was used for ex-
pression levels provided in Additional file 1: Table S1.
Immunoblotting
Cell pellets were lysed with 100 to 150 μl of protein lysis
buffer (50 mmol/L Tris, 150 mmol/L NaCl, 1% NP40,
0.25% deoxycholate with added inhibitors aprotinin,
AEBSF, leupeptin, pepstatin, sodium orthovanadate, and
sodium pyruvate, respectively phosphatase inhibitor
cocktails „2“ and „1“ or „3“ (Sigma, St. Louis, MO). Pro-
tein from cell lysates (75 to 200 μg protein) was used for
whole cell protein analysis after denaturing by Western
immunoblot assays using a BioRad Criterion system.
Nonspecific binding was blocked by incubating the blots
in nonfat dry milk or BSA. Primary antibodies were
incubated for one hour or over night, followed by several
washes of Tris-buffered saline (TBS) containing 0.005%
Tween 20. The appropriate secondary antibody was
applied for 30‘, followed by several washes. Antibody-re-
active proteins were detected using a LI-COR Odyssey®
fluorescence optical system.
Immunophenotyping
Intracellular (phospho-)AKT protein expression levels
were assayed as follows: Cells were fixed and permeabilized
using the Fix & Perm® Fixation and Permeabilization kit
(ADG-An der Grub Bioresearch, Kaumberg, Austria). Un-
labeled primary AKT antibodies were added in a 1:1000
dilution to the cell suspension and incubated for 1 hour at
room temperature followed by PBS washing and resuspen-
sion. Fluorescent dye-conjugated secondary antibodies
were added in a 1:10 000 dilution and cells were incubated
for 30 min at room temperature. After rinsing and resus-
pension, (phospho-)AKT protein expression levels were
assayed using a FACScalibur® flow cytometer loaded with
CellQuest® analysis software (BD, Heidelberg, Germany).
Site-directed mutagenesis and generation of a Ba/F3 cell
line expressing KIT, ABL1 or FLT3 isoforms
To compare constitutive activation of AKT mediated by
autoactive tyrosine kinase signaling in a homologous
cellular background, an isogenic cell model (Ba/F3) ex-
pressing different human tyrosine kinase mutations was
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(Ba/F3) was transfected with plasmid vectors containing
cDNA of human (mutant) FLT3 and KIT isoforms, as well
as the BCR/ABL1 fusion mutation isoform. Gain-of func-
tion tyrosine kinase mutations lead to factor-independency.
Site-directed mutagenesis and generation of a Ba/F3
cell lines stably expressing mutant KIT D816V, D816Y,
FLT3 ITD, D835V, D835Y, K663Q, BCR/ABL1 and
FLT3 wildtype was previously performed as described
before [36,53-55].
FLT3 S451F cDNA cloned into a pCMVneo plasmid
vector [53] was generously provided by Dr. Fröhling,
University of Ulm, Germany. KIT wildtype cDNA cloned
into a pJP1563 plasmid vector was obtained from the
DNASU Plasmid Repository at the Biodesign Institute
of the Arizona State University (ASU). Lipofection trans-
fection into the parental Ba/F3 cell line was performed
to stably express KIT wildtype or mutant FLT3 S451F by
double selection for neomycin (pCMVneo plasmid),
blasticidin (pJP1563 plasmid) or gentamicin (G418; all
other plasmids) resistance and IL-3-independent growth.
The Ba/F3 KIT wildtype cell line was cultured using
recombinant human stem cell factor (SCF/KIT Ligand,
R&D, Minneapolis, MN) as a growth supplement.
Apoptosis and proliferation assays
Cells were treated in dilution series with the respective
small molecule inhibitor.
Translocation of phosphatidylserine from the inner to the
outer leaflet of the plasma membrane as an early indicator
of apoptosis was analyzed using an Annexin V-based assay
(Immunotech, Marseilles, France) and a FACScalibur® flow
cytometer loaded with CellQuest® analysis software (BD,
Heidelberg, Germany) [35].
Cellular proliferation was measured using an 2,3-bis
[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-
carboxanilide inner salt (XTT)–based assay (Sigma) as de-
scribed previously [35].
Cell cycle assay
A propidium iodide-based flow cytometry assay was
assessed as described previously [56]. In short, a propidium
iodide stain assay is used to segregate cells according to
the DNA content, which is graphically shown in a histo-
gram plot (high content in G2/M, intermediate content in
S-phase, low content in G1/G0 and lowest content in
dead/apoptotic cells, which defines a sub-G1/G0 fraction),
Data analysis
Linear regression dose effect plots to calculate IC50s
were computed with values in between upper and lower
threshold doses of minimal/maximal dose effects using
Calcusyn Software (Biosoft, Cambridge, UK), which is
based on equations provided by Chou and Talaly [37].Isobologram analyses were performed as we have previ-
ously described [54,55]. In short, cells were treated with
fixed ratios in relationship to the individual agent ED and
data was analyzed using the method of Chou and Talalay
to produce isobolograms. This allowed calculation of
combination indices (CI). The CI provide a numerical
description of the effects of a combination treatment.
Specifically, a CI < 1 indicates synergy, a CI = 1 indicates
an additive effect, and a CI > 1 indicates antagonism of
the two agents.
Additional files
Additional file 1: Table S1. AKT Phospho-Expression Analysis - Patient
Characteristics.
Additional file 2: Figure S1. NVP-BGT226 and NVP-BEZ235 target AKT-
mediated viability of native leukemia cells ex vivo. NVP-BGT226 and NVP-
BEZ235 target AKT-mediated viability of native leukemia cells. (A) A flow
cytometry based assay using native acute leukemia cells treated with
NVP-BGT226 or NVP-BEZ235 demonstrates variable proapoptotic efficacy.
The average of three acute leukemia patients is shown. Standard
deviations reveal relatively high inter-individual differences in sensitivity
towards both inhibitors – with NVP-BGT226 being the more potent
agent. (B) AKT signaling is a target of dual PI3K/MTOR inhibition in native
leukemia blasts. An immunoblot experiment using whole cell lysates of
two patients is shown. Actin blotting is used as a loading control.
Additional file 3: Figure S2. PI3K/MTOR inhibition in imatinib-
resistance models. Dual PI3K/MTOR inhibition is effective in tyrosine
kinase inhibitor-resistant cell models. Two cell models, the HMC1 mast
cell leukemia cell strains (A and B) and two GIST cell lines (C and D; for
more information about the cell lines, see comments below), were
established to compare primary imatinib-sensitive versus secondary
imatinib-insensitive mutation patterns with regard to sensitivity to NVP-
BGT226 (A and C) or NVP-BEZ235 (B and D). Dose-effect plots are
provided indicating sensitivity profiles of both dual PI3K/MTOR inhibitors
that are independent of the sensitivity patterns for imatinib. Linear
regression analyses to calculate IC50 estimates are provided for all cell
lines. [HMC1.1: Mast cell leukemia cell line, harboring a KIT V560G
mutation; HMC1.2: sister cell line of HMC1.1, harboring an additional KIT
D816V mutation; GIST882: gastrointestinal stromal tumor harboring an
imatinib-sensitive KIT K642E mutation; GIST48: gastrointestinal stromal
tumor harboring an imatinib-sensitive V560D mutation plus a secondary
imatinib-insensitive activation loop mutation (D820A)].
Abbreviations
ABL1: Abelson murine leukemia viral oncogene homolog 1; AKT =
PKB: Protein kinase B; AML: Acute myeloid leukemia; ALL: Acute lymphoid
leukemia; CI: Combination index; CML: Chronic myeloid leukemia;
ED50: Effective dose to inhibit 50% of a defined endpoint; EVI1: Ecotropic
virus integration site 1; FLT3: FMS-like tyrosine kinase 3; GIST: Gastrointestinal
stromal tumor; IC50: Concentration sufficient to achieve a 50% inhibition;
IL3: Interleukin 3; ITD: Internal tandem duplication; KIT: v-kit Hardy-
Zuckerman 4 feline sarcoma viral oncogene homolog; mTOR: Mammalian
target of rapamycin; MTORC1/2: Mammalian target of rapamycin complex 1/2;
PI3K: Phosphoinositide 3 kinase; PTEN: Phosphatase and Tensin homolog;
Rictor: Rapamycin-insensitive companion of mTOR; Raptor: Regulatory
associated protein of mTOR; TK: Tyrosine kinase; TKI: Tyrosine kinase inhibitor;
TKD: Tyrosine kinase domain; XTT: 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilid-sodium salt.
Competing interests
Dr. Kampa-Schittenhelm: no conflicts.
Dr. Heinrich Consultant Novartis, MolecularMD, Research funding: Novartis,
Ariad, Imclone, AROG, Equity interest: MolecularMD.
Figen Akmut: no conflicts.
Katharina Henriette Rasp: no conflicts.
Kampa-Schittenhelm et al. Molecular Cancer 2013, 12:46 Page 17 of 18
http://www.molecular-cancer.com/content/12/1/46Barbara Illing: no conflicts.
Dr. Hartmut Döhner: Consultant: Novartis, Celgene, Boehringer Ingelheim,
Ambit.
Dr. Konstanze Döhner: Consultant: Novartis.
Dr. Schittenhelm: no conflicts.
Authors’ contributions
KS designed research, performed research, analyzed data and wrote the
paper. MH analyzed data, and wrote the paper. FA performed research and
analyzed data. KR performed research analyzed data. BI performed research
analyzed data. HD analyzed data, and wrote the paper. KD analyzed data,
and wrote the paper. MS designed research, performed research, analyzed
data and wrote the paper. All authors read and approved the final
manuscript.
Acknowledgements
We thank the core facilities of the Medizinische Universitätsklinik Tübingen
for excellent technical assistance.
We acknowledge support by Deutsche Forschungsgemeinschaft and Open
Access Publishing Fund of the University of Tübingen.
Supported
In part by the Deutsche Krebshilfe Foundation (MMS, KKS), the fortüne-
Program of the Tübingen Medical Faculty (Nr. 1490-0-0, MMS and 11836-0-0,
KMK), the IZKF Program of the Medical Faculty Tübingen (MMS) and the José
Carreras Scholarship Program (KKS), the Ludwig Hiermaier Foundation of the
Comprehensive Cancer Center Tübingen (MMS), a Merit Review Grant from
the Department of Veterans Affairs (MCH) and a grant from the Leukemia
and Lymphoma Society (MCH), GIST Cancer Research Fund (MCH) and the
Life Raft Group (MCH).
Author details
1Department of Hematology, Oncology, Rheumatology, Immunology and
Pulmology, University Hospital Tübingen, Otfried-Müller-Straße 10, 72076,
Tübingen, Germany. 2Portland VA Medical Center and OHSU Knight Cancer
Institute, Portland, OR, USA. 3Department of Internal Medicine III, University
Hospital Ulm, Ulm, Germany.
Received: 14 October 2012 Accepted: 6 May 2013
Published: 24 May 2013
References
1. Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J
Med 2004, 350:1535–1548.
2. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK,
Dombret H, Fenaux P, Grimwade D, Larson RA, et al: Diagnosis and
management of acute myeloid leukemia in adults: recommendations
from an international expert panel, on behalf of the European
LeukemiaNet. Blood 2010, 115:453–474.
3. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville
R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase
in the blast crisis of chronic myeloid leukemia and acute lymphoblastic
leukemia with the Philadelphia chromosome. N Engl J Med 2001,
344:1038–1042.
4. Schittenhelm M, Aichele O, Krober SM, Brummendorf T, Kanz L, Denzlinger C:
Complete remission of third recurrence of acute myeloid leukemia after
treatment with imatinib (STI-571). Leuk Lymphoma 2003, 44:1251–1253.
5. Kindler T, Breitenbuecher F, Marx A, Hess G, Gschaidmeier H, Gamm H,
Kirkpatrick CJ, Huber C, Fischer T: Sustained complete hematologic
remission after administration of the tyrosine kinase inhibitor imatinib
mesylate in a patient with refractory, secondary AML. Blood 2003,
101:2960–2962.
6. Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J,
Peschel C, Kirkpatrick CJ, Theobald M, et al: Efficacy and safety of imatinib
in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004,
103:3644–3654.
7. Kindler T, Lipka DB, Fischer T: FLT3 as a therapeutic target in AML: still
challenging after all these years. Blood 2010, 116:5089–5102.
8. Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream.
Cell 2007, 129:1261–1274.9. Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG,
Gritsman K: Constitutively active AKT depletes hematopoietic stem cells
and induces leukemia in mice. Blood 2010, 115:1406–1415.
10. Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwable J, Buerger
H, Muller-Tidow C, Choudhary C, McMahon M, et al: Constitutive activation
of Akt by Flt3 internal tandem duplications is necessary for increased
survival, proliferation, and myeloid transformation. Cancer Res 2005,
65:9643–9650.
11. Brognard J, Clark AS, Ni Y, Dennis PA: Akt/protein kinase B is constitutively
active in non-small cell lung cancer cells and promotes cellular survival
and resistance to chemotherapy and radiation. Cancer Res 2001,
61:3986–3997.
12. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in
human cancer. Nat Rev Cancer 2002, 2:489–501.
13. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A,
Powell SM, Riggins GJ, et al: High frequency of mutations of the PIK3CA
gene in human cancers. Science 2004, 304:554.
14. Kim MS, Jeong EG, Yoo NJ, Lee SH: Mutational analysis of oncogenic AKT
E17K mutation in common solid cancers and acute leukaemias.
Br J Cancer 2008, 98:1533–1535.
15. Hollander MC, Blumenthal GM, Dennis PA: PTEN loss in the continuum of
common cancers, rare syndromes and mouse models. Nat Rev Cancer
2011, 11:289–301.
16. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM,
Weiss J, Fischer F, Frommolt P, et al: PTEN loss contributes to erlotinib
resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
Cancer Res 2009, 69:3256–3261.
17. Zenz T, Dohner K, Denzel T, Dohner H, Stilgenbauer S, Bullinger L: Chronic
lymphocytic leukaemia and acute myeloid leukaemia are not associated
with AKT1 pleckstrin homology domain (E17K) mutations. Br J Haematol
2008, 141:742–743.
18. Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, Moses T, Carpten JD:
PI3K/AKT pathway activation in acute myeloid leukaemias is not
associated with AKT1 pleckstrin homology domain mutation.
Br J Haematol 2008, 140:344–347.
19. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco
L: Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical
implications for human acute myeloid leukemia. Leukemia 2006,
20:911–928.
20. Maira SM, Finan P, Garcia-Echeverria C: From the bench to the bed side:
PI3K pathway inhibitors in clinical development. Curr Top Microbiol
Immunol 2010, 347:209–239.
21. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska
E, Sosman J, McDermott D, Bodrogi I, et al: Temsirolimus, interferon alfa,
or both for advanced renal-cell carcinoma. N Engl J Med 2007,
356:2271–2281.
22. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM,
Benzaquen D, Laurent G, Huguet F, Payrastre B: Antileukemic activity of
rapamycin in acute myeloid leukemia. Blood 2005, 105:2527–2534.
23. Schittenhelm M, Theil A, Shiraga S, Lee F, Heinrich M: Dasatinib and rapamycin
synergistically inhibit the proliferation of cells expressing oncogenic KIT kinase via
global inhibition of AKT-dependent signaling. AACR Annual Meeting; 2007. pp.
Abstract 5416: AACR Meeting Abstracts; 2007:Abstract 5416.
24. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N,
Dreyfus F, Mayeux P, Lacombe C, Bouscary D: Mammalian target of
rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt
by up-regulating insulin-like growth factor-1 receptor signaling in acute
myeloid leukemia: rationale for therapeutic inhibition of both pathways.
Blood 2008, 111:379–382.
25. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A,
Sasaki AT, Thomas G, Kozma SC, et al: Inhibition of mTORC1 leads to
MAPK pathway activation through a PI3K-dependent feedback loop in
human cancer. J Clin Invest 2008, 118:3065–3074.
26. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F,
Hicklin DJ, Ludwig DL, et al: mTOR inhibition induces upstream receptor
tyrosine kinase signaling and activates Akt. Cancer Res 2006,
66:1500–1508.
27. Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY: Novel
phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays
potent growth-inhibitory activity against human head and neck cancer
cells in vitro and in vivo. Clin Cancer Res 2011, 17:7116–7126.
Kampa-Schittenhelm et al. Molecular Cancer 2013, 12:46 Page 18 of 18
http://www.molecular-cancer.com/content/12/1/4628. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S,
Chene P, De Pover A, Schoemaker K, et al: Identification and
characterization of NVP-BEZ235, a new orally available dual
phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor
with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7:1851–1863.
29. Polak R, Buitenhuis M: The PI3K/PKB signaling module as key regulator of
hematopoiesis: implications for therapeutic strategies in leukemia.
Blood 2012, 119:911–923.
30. Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade
C, Attal M, Payrastre B, Demur C, Recher C: The level of AKT
phosphorylation on threonine 308 but not on serine 473 is associated
with high-risk cytogenetics and predicts poor overall survival in acute
myeloid leukaemia. Leukemia 2009, 23:1029–1038.
31. Shan X, Czar MJ, Bunnell SC, Liu P, Liu Y, Schwartzberg PL, Wange RL:
Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk
to the plasma membrane and hyperresponsiveness to CD3 stimulation.
Mol Cell Biol 2000, 20:6945–6957.
32. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier
M, Willems L, Park S, Macone A, et al: Dual inhibition of PI3K and
mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for
acute myeloid leukemia. Clin Cancer Res 2010, 16:5424–5435.
33. Panwalkar A, Verstovsek S, Giles FJ: Mammalian target of rapamycin
inhibition as therapy for hematologic malignancies. Cancer 2004,
100:657–666.
34. Bach M, Larance M, James DE, Ramm G: The serine/threonine kinase ULK1
is a target of multiple phosphorylation events. Biochem J 2011,
440:283–291.
35. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY,
Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-
354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity
of wild-type, juxtamembrane, and activation loop mutant KIT
isoforms associated with human malignancies. Cancer Res 2006,
66:473–481.
36. Schittenhelm MM, Yee KW, Tyner JW, McGreevey L, Haley AD, Town A,
Griffith DJ, Bainbridge T, Braziel RM, O'Farrell AM, et al: FLT3 K663Q is a
novel AML-associated oncogenic kinase: Determination of biochemical
properties and sensitivity to Sunitinib (SU11248). Leukemia 2006,
20:2008–2014.
37. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the
combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme
Regul 1984, 22:27–55.
38. Kirstein MM, Boukouris AE, Pothiraju D, Buitrago-Molina LE, Marhenke S,
Schutt J, Orlik J, Kuhnel F, Hegermann J, Manns MP, Vogel A: Activity of the
mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235
and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
Liver Int 2013. doi:10.1111/liv.12126.
39. Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R:
Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly
effective in multiple myeloma. Anticancer Drugs 2012, 23:131–138.
40. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers
KJ, Wang S, Hunt JP, et al: Validation of ITD mutations in FLT3 as a
therapeutic target in human acute myeloid leukaemia. Nature 2012,
485:260–263.
41. Bauer S, Duensing A, Demetri GD, Fletcher JA: KIT oncogenic signaling
mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-
kinase/AKT is a crucial survival pathway. Oncogene 2007, 26:7560–7568.
42. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara
H, Butterfield JH, Ashman LK, Kanayama Y, et al: Identification of mutations
in the coding sequence of the proto-oncogene c-kit in a human mast
cell leukemia cell line causing ligand-independent activation of c-kit
product. J Clin Invest 1993, 92:1736–1744.
43. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon
G, Longley BJ: The c-KIT mutation causing human mastocytosis is
resistant to STI571 and other KIT kinase inhibitors; kinases with
enzymatic site mutations show different inhibitor sensitivity profiles
than wild-type kinases and those with regulatory-type mutations.
Blood 2002, 99:1741–1744.
44. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA,
Demetri GD: STI571 inactivation of the gastrointestinal stromal tumor
c-KIT oncoprotein: biological and clinical implications. Oncogene 2001,
20:5054–5058.45. Bauer S, Yu LK, Demetri GD, Fletcher JA: Heat shock protein 90 inhibition
in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006,
66:9153–9161.
46. Breitenbuecher F, Markova B, Kasper S, Carius B, Stauder T, Bohmer FD,
Masson K, Ronnstrand L, Huber C, Kindler T, Fischer T: A novel molecular
mechanism of primary resistance to FLT3-kinase inhibitors in AML.
Blood 2009, 113:4063–4073.
47. Groschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, van
Putten WJ, Kayser S, Verdonck LF, Lubbert M, et al: High EVI1 expression
predicts outcome in younger adult patients with acute myeloid
leukemia and is associated with distinct cytogenetic abnormalities.
J Clin Oncol 2010, 28:2101–2107.
48. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai
S, Sato T, Shimabe M, Nakagawa M, et al: Evi1 represses PTEN expression
and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
Blood 2011, 117:3617–3628.
49. Burris H, Rodon J, Sharma S, Herbst R, Tabernero J, Infante J, Silva A,
Demanse D, Hackl H, Baselga J: First-in-human phase I study of the oral
PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. In
ASCO Annual Meeting. J Clin Oncol 2010, 28:Abstract 3005.
50. Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M,
Melendez Cuero M, Stutvoet S, Birle D, et al: Phase I safety,
pharmacokinetic, and pharmacodynamic study of the oral
phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients
with advanced solid tumors. Ann Oncol 2012, 23:2399–2408.
51. Glienke W, Maute L, Wicht J, Bergmann L: The dual PI3K/mTOR inhibitor
NVP-BGT226 induces cell cycle arrest and regulates Survivin gene
expression in human pancreatic cancer cell lines. Tumour Biol 2012,
33:757–765.
52. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG: FLT3 mutations in
acute myeloid leukemia cell lines. Leukemia 2003, 17:120–124.
53. Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R,
Dohner H, Dohner K, Ebert BL, et al: Identification of driver and passenger
mutations of FLT3 by high-throughput DNA sequence analysis and
functional assessment of candidate alleles. Cancer Cell 2007, 12:501–513.
54. Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T,
Cherrington JM, Heinrich MC: Synergistic effect of SU11248 with
cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
Blood 2004, 104:4202–4209.
55. Schittenhelm MM, Kampa KM, Yee KW, Heinrich MC: The FLT3 inhibitor
tandutinib (formerly MLN518) has sequence-independent synergistic
effects with cytarabine and daunorubicin. Cell Cycle 2009, 8:2621–2630.
56. Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S,
Hartmann JT, Bokemeyer C, Mayer F: Cell-cycle progression and response
of germ cell tumors to cisplatin in vitro. Int J Oncol 2006, 29:471–479.
doi:10.1186/1476-4598-12-46
Cite this article as: Kampa-Schittenhelm et al.: Cell cycle-dependent
activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute
leukemia. Molecular Cancer 2013 12:46.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
